Transcatheter arterial chemoembolization improves clinical efficacy and life quality of patients with lung cancer and reduces adverse reactions.

OBJECTIVE: To determine the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) for patients with lung cancer (LC). METHODS: A total of 513 inpatients with LC admitted to our hospital from January 2012 to January 2020 were analyzed retrospectively. Based on different treatment methods, they were assigned into a control group (CG; n=249) for traditional bronchial artery infusion (BAI) and an experimental group (EG; n=264) for TACE, with shared chemotherapy drugs and treatment courses. The two groups were compared with respect to clinical efficacy, pre- and post-treatment pulmonary function, adverse reactions, as well as negative emotions and quality of life (QoL) scores. RESULTS: The curative effect in EG was far superior to CG (P<0.05). In comparison with CG, the pulmonary function in EG was better and the incidence of adverse reactions was lower after treatment (P<0.05). The negative emotions and the QoL were improved in both groups, with more distinct improvement in EG compared with CG (P<0.05). CONCLUSIONS: With higher safety and efficacy, TACE can improve the clinical efficacy and QoL of patients with LC while relieving bad mood and reducing adverse reactions.